Regencell Bioscience Holdings Ltd

NASDAQ RGC

Download Data

Regencell Bioscience Holdings Ltd Capital Expenditures for the Trailing 12 Months (TTM) ending September 30, 2023: USD -0.00

Regencell Bioscience Holdings Ltd Capital Expenditures is USD -0.00 for the Trailing 12 Months (TTM) ending September 30, 2023, a 100.00% change year over year. Capital Expenditures represent the amount of money spent on acquiring or improving long-term assets, such as property, plant, and equipment.
  • Regencell Bioscience Holdings Ltd Capital Expenditures for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -205.71 M, a -423,611.38% change year over year.
  • Regencell Bioscience Holdings Ltd Capital Expenditures for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -48.55 K, a 99.98% change year over year.
  • Regencell Bioscience Holdings Ltd Capital Expenditures for the Trailing 12 Months (TTM) ending December 31, 2017 was USD -250.40 M, a -16.52% change year over year.
  • Regencell Bioscience Holdings Ltd Capital Expenditures for the Trailing 12 Months (TTM) ending December 31, 2016 was USD -214.90 M.
NASDAQ: RGC

Regencell Bioscience Holdings Ltd

CEO Mr. Yat-Gai Au
IPO Date July 16, 2021
Location Hong Kong
Headquarters First Commercial Building, Causeway Bay, Hong Kong
Employees 12
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Similar companies

EGRX

Eagle Pharmaceuticals Inc

NA

NA

PAHC

Phibro Animal Health Corporation

NA

NA

PROC

Procaps Group SA

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email